Growth may be starting to pick up in the med-tech world, but Stryker (NYSE: SYK )
is still finding a way to stand out from the crowd. Stryker had a
surprisingly strong quarter in its reconstructive products business, and
the long-term outlook for instruments, endoscopy, and neuro/spine are
all appealing. Add in upside from the MAKO Surgical acquisition and,
while Stryker may not be a bargain-basement stock anymore, it still
holds some appeal for long-term investors.
Follow this link for more:
Stryker Corporation Offering Some Of The Best Growth Prospects In Large Med-Tech
No comments:
Post a Comment